Imugene sees positive early signals in Phase 1 VAXINIA study

–News Direct–

Imugene Ltd (ASX:IMU) (OTCMKTS:IUGNF) CEO Leslie Chong talks Proactive through a clinical trial update of its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial evaluating the safety and efficacy of novel cancer-killing virus CF33-hNIS (VAXINIA). Chong says the early positive response data being seen at the mid-dose level in hard-to-treat bile duct cancer suggests that VAXINIA may be a potent anti-cancer drug as IMU interrogates higher dose levels.

Chong said: As we near closer to opening and completing the final cohorts that were planned at the beginning of the trial, we have an opportunity to expand the trial by enrolling patients in additional cohorts for the monotherapy dose escalation component.

This will provide us with a far more robust data set to analyse and speak to at the conclusion of the MAST study, and provide us with a stronger platform as we further the clinical development of CF33 and VAXINIA.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

View source version on

Imugene Ltd

comtex tracking